LU86099A1 - Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant - Google Patents

Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant Download PDF

Info

Publication number: LU86099A1
Authority: LU; Luxembourg
Prior art keywords: verapamil; microgranules; esters; dosage form; microporous membrane
Prior art date: 1985-09-30

Application number

LU86099A

Other languages

English (en)

French (fr)

Inventor

De Boeck Arthur

Baudier Philippe

Original Assignee

Pharlyse

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-09-30

Filing date

1985-09-30

Publication date

1987-04-02

1985-09-30 Application filed by Pharlyse filed Critical Pharlyse

1985-09-30 Priority to LU86099A priority Critical patent/LU86099A1/fr

1986-09-25 Priority to DE8686870136T priority patent/DE3685392D1/de

1986-09-25 Priority to EP86870136A priority patent/EP0217778B1/de

1986-09-25 Priority to AT86870136T priority patent/ATE76290T1/de

1986-09-30 Priority to US06/913,279 priority patent/US4832958A/en

1987-04-02 Publication of LU86099A1 publication Critical patent/LU86099A1/fr

Links

SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 title claims abstract description 55
229960001722 verapamil Drugs 0.000 title claims abstract description 44
238000004519 manufacturing process Methods 0.000 title claims description 10
229940126601 medicinal product Drugs 0.000 title claims description 3
238000013265 extended release Methods 0.000 title description 4
239000012982 microporous membrane Substances 0.000 claims abstract description 19
239000000203 mixture Substances 0.000 claims abstract description 13
239000000080 wetting agent Substances 0.000 claims abstract description 13
229920000642 polymer Polymers 0.000 claims abstract description 12
239000000126 substance Substances 0.000 claims abstract description 11
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 9
239000000314 lubricant Substances 0.000 claims abstract description 9
239000004014 plasticizer Substances 0.000 claims abstract description 9
239000002671 adjuvant Substances 0.000 claims abstract description 8
125000005395 methacrylic acid group Chemical group 0.000 claims abstract description 7
230000002496 gastric effect Effects 0.000 claims abstract description 6
239000013543 active substance Substances 0.000 claims abstract description 5
239000000945 filler Substances 0.000 claims abstract description 5
150000003839 salts Chemical class 0.000 claims abstract description 4
239000002253 acid Substances 0.000 claims abstract description 3
239000002552 dosage form Substances 0.000 claims description 28
239000003814 drug Substances 0.000 claims description 16
235000014113 dietary fatty acids Nutrition 0.000 claims description 15
239000000194 fatty acid Substances 0.000 claims description 15
229930195729 fatty acid Natural products 0.000 claims description 15
-1 pclyvinyipyrrolidone Chemical class 0.000 claims description 15
229930006000 Sucrose Natural products 0.000 claims description 13
239000005720 sucrose Substances 0.000 claims description 13
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 10
150000002148 esters Chemical class 0.000 claims description 9
150000004665 fatty acids Chemical class 0.000 claims description 7
229920000136 polysorbate Polymers 0.000 claims description 7
239000000454 talc Substances 0.000 claims description 7
229910052623 talc Inorganic materials 0.000 claims description 7
229920003134 Eudragit® polymer Polymers 0.000 claims description 6
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 6
230000002378 acidificating effect Effects 0.000 claims description 6
239000011248 coating agent Substances 0.000 claims description 6
238000000576 coating method Methods 0.000 claims description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
239000002518 antifoaming agent Substances 0.000 claims description 5
TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 claims description 5
239000000049 pigment Substances 0.000 claims description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
102220289725 rs778831047 Human genes 0.000 claims description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 4
229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 claims description 4
239000002216 antistatic agent Substances 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 4
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 4
239000012528 membrane Substances 0.000 claims description 4
229920002545 silicone oil Polymers 0.000 claims description 4
239000000600 sorbitol Substances 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 4
229960000881 verapamil hydrochloride Drugs 0.000 claims description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 claims description 3
239000000787 lecithin Substances 0.000 claims description 3
235000010445 lecithin Nutrition 0.000 claims description 3
235000019359 magnesium stearate Nutrition 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
229920000053 polysorbate 80 Polymers 0.000 claims description 3
239000012730 sustained-release form Substances 0.000 claims description 3
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
229920003151 Eudragit® RL polymer Polymers 0.000 claims description 2
229920003152 Eudragit® RS polymer Polymers 0.000 claims description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
229930195725 Mannitol Natural products 0.000 claims description 2
235000021314 Palmitic acid Nutrition 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 2
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 2
235000010980 cellulose Nutrition 0.000 claims description 2
229920002678 cellulose Polymers 0.000 claims description 2
239000001913 cellulose Substances 0.000 claims description 2
235000019416 cholic acid Nutrition 0.000 claims description 2
239000002812 cholic acid derivative Substances 0.000 claims description 2
150000001842 cholic acids Chemical class 0.000 claims description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 2
150000002170 ethers Chemical class 0.000 claims description 2
FSXVSUSRJXIJHB-UHFFFAOYSA-M ethyl prop-2-enoate;methyl 2-methylprop-2-enoate;trimethyl-[2-(2-methylprop-2-enoyloxy)ethyl]azanium;chloride Chemical compound [Cl-].CCOC(=O)C=C.COC(=O)C(C)=C.CC(=C)C(=O)OCC[N+](C)(C)C FSXVSUSRJXIJHB-UHFFFAOYSA-M 0.000 claims description 2
150000002191 fatty alcohols Chemical class 0.000 claims description 2
239000001087 glyceryl triacetate Substances 0.000 claims description 2
235000013773 glyceryl triacetate Nutrition 0.000 claims description 2
239000008187 granular material Substances 0.000 claims description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 2
235000013980 iron oxide Nutrition 0.000 claims description 2
VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 claims description 2
239000008101 lactose Substances 0.000 claims description 2
239000000594 mannitol Substances 0.000 claims description 2
235000010355 mannitol Nutrition 0.000 claims description 2
DNKKLDKIFMDAPT-UHFFFAOYSA-N n,n-dimethylmethanamine;2-methylprop-2-enoic acid Chemical compound CN(C)C.CC(=C)C(O)=O.CC(=C)C(O)=O DNKKLDKIFMDAPT-UHFFFAOYSA-N 0.000 claims description 2
235000021313 oleic acid Nutrition 0.000 claims description 2
150000002889 oleic acids Chemical class 0.000 claims description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 2
229920000056 polyoxyethylene ether Polymers 0.000 claims description 2
239000001957 sucroglyceride Substances 0.000 claims description 2
235000010964 sucroglyceride Nutrition 0.000 claims description 2
235000000346 sugar Nutrition 0.000 claims description 2
238000013268 sustained release Methods 0.000 claims description 2
OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 2
229960002622 triacetin Drugs 0.000 claims description 2
229920002554 vinyl polymer Polymers 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims 1
239000004743 Polypropylene Substances 0.000 claims 1
150000001298 alcohols Chemical class 0.000 claims 1
150000001875 compounds Chemical class 0.000 claims 1
229960002380 dibutyl phthalate Drugs 0.000 claims 1
LUJQXGBDWAGQHS-UHFFFAOYSA-N ethenyl acetate;phthalic acid Chemical compound CC(=O)OC=C.OC(=O)C1=CC=CC=C1C(O)=O LUJQXGBDWAGQHS-UHFFFAOYSA-N 0.000 claims 1
UPBDXRPQPOWRKR-UHFFFAOYSA-N furan-2,5-dione;methoxyethene Chemical compound COC=C.O=C1OC(=O)C=C1 UPBDXRPQPOWRKR-UHFFFAOYSA-N 0.000 claims 1
150000002334 glycols Chemical class 0.000 claims 1
210000003734 kidney Anatomy 0.000 claims 1
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 1
229920000141 poly(maleic anhydride) Polymers 0.000 claims 1
229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 claims 1
229920000573 polyethylene Polymers 0.000 claims 1
229920001155 polypropylene Polymers 0.000 claims 1
229920002744 polyvinyl acetate phthalate Polymers 0.000 claims 1
150000008163 sugars Chemical class 0.000 claims 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
230000002035 prolonged effect Effects 0.000 abstract description 9
210000000936 intestine Anatomy 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 description 10
229940079593 drug Drugs 0.000 description 8
238000000034 method Methods 0.000 description 7
238000005507 spraying Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
239000002609 medium Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000006185 dispersion Substances 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012729 immediate-release (IR) formulation Substances 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
229940088024 isoptin Drugs 0.000 description 4
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
239000010931 gold Substances 0.000 description 3
229910052737 gold Inorganic materials 0.000 description 3
238000005259 measurement Methods 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
230000008569 process Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
206010002383 Angina Pectoris Diseases 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
206010057362 Underdose Diseases 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000001035 drying Methods 0.000 description 2
125000005456 glyceride group Chemical group 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
230000033764 rhythmic process Effects 0.000 description 2
238000007873 sieving Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
238000009736 wetting Methods 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
206010003225 Arteriospasm coronary Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
235000014066 European mistletoe Nutrition 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
235000011613 Pinus brutia Nutrition 0.000 description 1
241000018646 Pinus brutia Species 0.000 description 1
235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
244000269722 Thea sinensis Species 0.000 description 1
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
241000221012 Viscum Species 0.000 description 1
150000001252 acrylic acid derivatives Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
239000012738 dissolution medium Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000010410 dusting Methods 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000003292 glue Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000003921 oil Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000005498 phthalate group Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
229960002508 pindolol Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
238000004904 shortening Methods 0.000 description 1
239000011734 sodium Substances 0.000 description 1
238000005563 spheronization Methods 0.000 description 1
238000013112 stability test Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229960004605 timolol Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

LU86099A 1985-09-30 1985-09-30 Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant LU86099A1 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
LU86099A LU86099A1 (fr)	1985-09-30	1985-09-30	Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
DE8686870136T DE3685392D1 (de)	1985-09-30	1986-09-25	Galenische formen mit verzoegerter verapamil-freisetzung, deren herstellung und diese enthaltende arzneimittel.
EP86870136A EP0217778B1 (de)	1985-09-30	1986-09-25	Galenische Formen mit verzögerter Verapamil-Freisetzung, deren Herstellung und diese enthaltende Arzneimittel
AT86870136T ATE76290T1 (de)	1985-09-30	1986-09-25	Galenische formen mit verzoegerter verapamilfreisetzung, deren herstellung und diese enthaltende arzneimittel.
US06/913,279 US4832958A (en)	1985-09-30	1986-09-30	Galenic forms of prolonged release verapamil and medicaments containing them

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
LU86099A LU86099A1 (fr)	1985-09-30	1985-09-30	Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
LU86099		1985-09-30

Publications (1)

Publication Number	Publication Date
LU86099A1 true LU86099A1 (fr)	1987-04-02

Family

ID=19730554

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU86099A LU86099A1 (fr)	1985-09-30	1985-09-30	Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant

Country Status (5)

Country	Link
US (1)	US4832958A (de)
EP (1)	EP0217778B1 (de)
AT (1)	ATE76290T1 (de)
DE (1)	DE3685392D1 (de)
LU (1)	LU86099A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5254347A (en) *	1988-03-31	1993-10-19	Tanabe Seiyaku Co., Ltd.	Controlled release pharmaceutical preparation and method for producing the same
FI101344B1 (fi) *	1988-03-31	1998-06-15	Tanabe Seiyaku Co	Menetelmä valmistaa valmiste, josta kontrolloidusti vapautuu farmaseuttisesti aktiivista ainetta
DE3932378A1 (de) *	1989-09-28	1991-04-11	Knoll Ag	Feste arzneiform mit hohem verapamil-gehalt
US5364635A (en) *	1989-09-28	1994-11-15	Knoll Ag	Solid drug form with a high verapamil content
US5252337A (en) *	1991-06-25	1993-10-12	Eurand America, Inc.	Controlled release calcium channel blocker microcapsules
US5288505A (en) *	1991-06-26	1994-02-22	Galephar P.R., Inc., Ltd.	Extended release form of diltiazem
BE1006990A5 (nl) *	1993-04-22	1995-02-07	Univ Gent	Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
DK0797987T3 (da) *	1994-12-19	2004-02-16	Daiichi Seiyaku Co	Granulært præparat med langvarig frigivelse og fremgangsmåde til fremstilling deraf
US5695781A (en) *	1995-03-01	1997-12-09	Hallmark Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers
US6083532A (en) *	1995-03-01	2000-07-04	Duramed Pharmaceuticals, Inc.	Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6607751B1 (en) *	1997-10-10	2003-08-19	Intellipharamaceutics Corp.	Controlled release delivery device for pharmaceutical agents incorporating microbial polysaccharide gum
WO2001015668A1 (en)	1999-09-02	2001-03-08	Nostrum Pharmaceuticals, Inc.	Controlled release pellet formulation
US7108866B1 (en)	1999-12-10	2006-09-19	Biovall Laboratories International Srl	Chronotherapeutic diltiazem formulations and the administration thereof
US20060153914A1 (en) *	1999-12-10	2006-07-13	Biovail Laboratories International S.R.L.	Chronotherapeutic diltiazem formulations and the administration thereof
US20030195706A1 (en) *	2000-11-20	2003-10-16	Michael Korenberg	Method for classifying genetic data
US6676958B2 (en) *	2001-06-19	2004-01-13	Advanced Bioadjuvants, Llc	Adjuvant composition for mucosal and injection delivered vaccines
US8101209B2 (en) *	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20040005359A1 (en) *	2002-06-27	2004-01-08	Cheng Xiu Xiu	Controlled release oral dosage form
FR2845289B1 (fr) *	2002-10-04	2004-12-03	Ethypharm Sa	Spheroides, procede de preparation et compositions pharmaceutiques.
EP2112920B1 (de) *	2003-06-26	2018-07-25	Intellipharmaceutics Corp.	Protonenpumpeninhibitoren enthaltende kapseln, die verschieden aufgebaute untereinheiten zur verzögerten wirkstofffreisetzung enthalten
US8394409B2 (en) *	2004-07-01	2013-03-12	Intellipharmaceutics Corp.	Controlled extended drug release technology
US10624858B2 (en)	2004-08-23	2020-04-21	Intellipharmaceutics Corp	Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en)	2005-12-23	2018-09-04	Intellipharmaceutics Corp.	Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (en) *	2006-04-03	2007-10-11	Isa Odidi	Controlled release delivery device comprising an organosol coat
US10960077B2 (en)	2006-05-12	2021-03-30	Intellipharmaceutics Corp.	Abuse and alcohol resistant drug composition
US20080292663A1 (en) *	2007-05-22	2008-11-27	Gerber Jay D	Adjuvant compositions and methods for delivering vaccines
US20110150986A1 (en) *	2009-12-18	2011-06-23	Kristin Arnold	Quinine formulations, method of making, and metho of use thereof
WO2011083150A2 (en) *	2010-01-07	2011-07-14	Akron Molecules Gmbh	Obesity small molecules
GB201003734D0 (en)	2010-03-05	2010-04-21	Univ Strathclyde	Delayed prolonged drug delivery
GB201003731D0 (en)	2010-03-05	2010-04-21	Univ Strathclyde	Immediate/delayed drug delivery
GB201003766D0 (en)	2010-03-05	2010-04-21	Univ Strathclyde	Pulsatile drug release

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3113901A1 (de) *	1981-04-07	1982-10-28	Basf Ag, 6700 Ludwigshafen	Wirkstoffzubereitung zur oralen applikation
LU85058A1 (fr) *	1983-10-24	1985-06-19	Pharlyse	Comprimes pharmaceutiques a liberation prolongee,leur preparation et leur utilisation
DK62184D0 (da) *	1984-02-10	1984-02-10	Benzon As Alfred	Diffusionsovertrukket polydepotpraeparat

1985
- 1985-09-30 LU LU86099A patent/LU86099A1/fr unknown
1986
- 1986-09-25 DE DE8686870136T patent/DE3685392D1/de not_active Expired - Fee Related
- 1986-09-25 EP EP86870136A patent/EP0217778B1/de not_active Expired - Lifetime
- 1986-09-25 AT AT86870136T patent/ATE76290T1/de active
- 1986-09-30 US US06/913,279 patent/US4832958A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE3685392D1 (de)	1992-06-25
EP0217778A2 (de)	1987-04-08
US4832958A (en)	1989-05-23
ATE76290T1 (de)	1992-06-15
EP0217778A3 (en)	1987-12-09
EP0217778B1 (de)	1992-05-20

Publication	Publication Date	Title
EP0217778B1 (de)	1992-05-20	Galenische Formen mit verzögerter Verapamil-Freisetzung, deren Herstellung und diese enthaltende Arzneimittel
JP5808670B2 (ja)	2015-11-10	弱塩基性薬物を含む組成物及び徐放性剤形
CA2428782C (fr)	2013-01-08	Medicament a base de microcapsules d'anti-hyperglycemiant a liberation prolongee et son procede de preparation
EP1827396B1 (de)	2016-06-01	Orales medikament für die modifizierte freisetzung von mindestens einem wirkstoff in multimikrokapselform
JP5878022B2 (ja)	2016-03-08	抗コリン薬を具える放出制御組成物
EP0216743B1 (de)	1993-03-17	Galenische Formen des Verapamils, deren Herstellung sowie diese enthaltende Arzneimittel
FR2938431A1 (fr)	2010-05-21	Nouvelle composition a base d'acide gamma-hydroxybutyrique
JP5954890B2 (ja)	2016-07-20	２−オキソ−１−ピロリジン誘導体を含む持続放出製剤
EP1492531B1 (de)	2008-09-10	Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
EP1492511A2 (de)	2005-01-05	Orale suspension von mikrokapseln enthaltend wirkstoffe
CA2721232C (fr)	2016-03-29	Forme orale solide dotee d'un double profil de liberation comprenant des multiparticules
WO2011141241A1 (fr)	2011-11-17	Forme pharmaceutique orale alcoolo-resistante
EP0318398B1 (de)	1995-03-15	Form zur verzögerten Diltiazemfreisetzung sowie das daraus hergestellte Arzneimittel
EP1189602A1 (de)	2002-03-27	Morphinsulfat enthaltende mikrogranulate, verfahren zu deren herstellung und pharmazeutische zusammensetzungen
WO2006122925A2 (fr)	2006-11-23	Medicament oral a base d'inhibiteur de pompe a protons
CA2608911A1 (fr)	2006-11-30	Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2006087394A1 (fr)	2006-08-24	Forme pharmaceutique orale de losartan
FR2882259A1 (fr)	2006-08-25	Forme pharmaceutique orale multimicroparticulaire a liberation modifiee de losartan
FR2843881A1 (fr)	2004-03-05	Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
FR2884145A1 (fr)	2006-10-13	Forme pharmaceutique orale de losartan